You are here

Aile Hekimliğinde Akne Vulgaris Tedavisine Yaklaşım

Share
APPROACH TO TREATMENT OF ACNE VULGARIS IN FAMILY MEDICINE

Journal Name:

Publication Year:

Volume:

Number:

Sayfa Aralığı:: 
71-78

Publication Language:

Abstract (Original Language): 
Akne vulgaris, aile hekimleri ve dermatologların sıkça karşılaştıkları bir deri hastalığıdır; Tedavi edilmediğinde emosyonel ve fiziksel bozukluklara neden olarak sosyal izolasyon, iş bulma güçlüğü, depresyon ve intihara yol açabilmektedir. Hafif ve orta şiddette akne tedavisinin aile hekimi tarafından yapılması, tedaviye dirençli ve şiddetli akne olgularının dermatologa sevk edilmesi uygun bir yaklaşım olacaktır.
Abstract (2. Language): 
Acne vulgaris is a common skin disease, which is frequently seen by both family physicians and dermatologists. When acne is untreated, it can cause social isolation, difficulty in finding jobs, depression and suicide as a result of emotional and physical scar formation. Mild to moderate acne should be treated by family physicians appropriately. Patients should be referred to dermatol¬ogists when there is no response to the treatment or in the pres¬ence of severe acne.

Keywords (Original Language):

REFERENCES

References: 

1. Brown SK, Salita AR. Acne vulgaris. Lancet 1998; 351: 1871-6.
2. Befed WF. The evaluation and management of acne: economic considerations. J Am Acad Dermatol 1995; 32: 552-6.
3. Rudy SJ. Overview of the evaluation and management of acne vulgaris. Pediatric Nursing 2003; 29(4): 287-93.
4. Johnson BA, Nunley JR. Use of systemic agents in the treatment of acne vulgaris. Am Fam Physician 2000; 62: 1823-30.
5. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. BMJ 1979; 166: 1109-10.
6. Webster GF. Is it reasonable for dermatologists to treat acne? Arch Dermatol 1996; 132: 819-20.
7. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc SciMed 1985; 20: 425-9.
8. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139; 846-50.
9. Cotteril JA, Cunliffe WJ. Suicide in dermatological patients. Br J Dermatol
1997; 137: 246-50.
10. Cunliffe WJ. Unemployement and acne. Br J Dermatol 1986; 115: 386.
11. MacKie RM. Clinical Dermatology. 4. baskı. Hong Kong, Oxford University
Press ,1999; 205-9.
12. Braun FO, Plewig G, Wolff HH, Burgdorf WCH. Dermatology. 2. baskı. New York, Springer-Verlag, 2000; 1051-82.
13. Bershad SV. The modern age of acne therapy: A review of current therapeutic options. The Mount Sinai Journal of Medicine 2001; 68: 279-86.
14. Thiboutot DM, Strauss JS. Diseases of the sebaceous glands. Fitzpatrick's Dermatology in General Medicine'de. Ed.Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. 6. baskı. New York, McGraw-Hill,
2003;672-87.
15. Cunliffe WJ. Acne vulgaris. The past, the present and the future. Acta Derm Venereol Suppl 1985; 120: 34-8.
16. Pochi PE, Strauss JS. Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol 1964; 43: 383-8.
17. Knutson DD. Ultrastructural observations in acne vulgaris: the normal seba¬ceous follicle and acne lesions. J Invest Dermatol 1974; 62: 288-307.
18. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Propionibacterium le¬vels in patients with and without acne vulgaris. J Invest Dermatol 1975; 65:
382-4.
19. Shalita AR, Lee WL. Inflammatory acne. Dermatol Clin 1983; 1: 361-4.
20. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam
Med 2000; 9: 179-87.
21. Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SV.
Acne therapy: A methodologic review. J Am Acad Dermatol 2002; 47: 231¬40.
22. Russell JJ. Topical therapy for acne. Am Family Physician 2000; 61: 357-66.
23. Leyden JJ. Therapy for acne vulgaris. N Engl J Med 1997; 336: 1156-62.
24. Mills OH, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 1986;
10: 664-7.
25. Chalker DK, Shalita A, Smith JG, Swann RW. A double-blind study of the effectiveness of 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9: 933-6.
26. Tucker SB, Tausend R, Cochran R, Flannigan SA. Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. Br J Dermatol 1984; 110: 487-92.
27. Tschen E, Jones T. A new treatment for acne vulgaris combining benzoyl pe¬roxide with clindamycin. J Drugs Dermatol 2002; 1(2): 153-7.
28. Hurwitz S. The combined effect of vitamin A acid and benzoyl peroxide in
the treatment of acne. Cutis 1976; 17: 585-90.
29. Shalita AR, Rafal ES, Anderson DN, Yavel R, Landow S, Lee WL. Com¬pared efficacy and safety of tretinoin 0.1% microsphere gel alone and in com¬bination with benzoyl peroxide 6% cleanser for the treatment of acne vulga-
ris. Cutis 2003; 72: 167-72.
30. Mills OH, Berger RS. A double blind evaluation of tretinoin alone and in combination with erythromycin/benzoyl peroxide in acne vulgaris. Cutis
1992; 49: 12-5.
31. Filton A, Goa KL. Azaleic acid. A review of pharmacological properties and therapeutic efficacy in acne and hiperpigmentary skin disorders. Drugs 1991;
41: 780-98.
32. Orfanos CE, Ehlert R, Gollnick H. The retinoids. A review of their clinical
pharmacology and therapeutic use. Drugs 1987; 34: 459-503.
33. Shalita AR. Topical acne therapy. Dermatol Clin 1983; 1: 399-403.
34. Rietschel RL, Duncan SH. Clindamycin phosphate used in combination with tretinoin in the treatment of acne. Int J Dermatol 1983; 22: 41-3.
35. Bergfel F. The evolving of retinoids in the management of cutaneous condi¬tions. Clinician 1998; 16: 1-32.
36. Kligman AM, Mills OH, McGinley KJ, Leyden JJ. Acne therapy with tre-tinoin in combination with antibiotics. Acta Derm Venereol Suppl 1975; 74:
111-5.
37. Cunlife WJ, Caputo R, Dreno B ve ark. Clinical efficacy and safety com¬parison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol 1997; 36: 126-34.
Türkiye
38. Caron D, Sorba V, Kerrouche N, Cluas A. Split face comparison of adapa-lene 0.1% gel and tretinoin 0.025 % gel in acne patients. J Am Acad Derma-
tol 1997; 36: 110-2.
39. Wolf JE Jr, Kaplan D, Kraus SJ ve ark. Efficacy and tolerability of com¬bined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomised, investigator blinded study. J Am Acad Dermatol
2003; 49: 211-7.
40. Cunlife WJ, Meynadier L, Alirezai M, George SA, Coutts I, Roseeuv DI.
Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the effi¬cacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003; 49: 218-26.
41. Leyden J. Open-label evaluation of topical antimicrobial and anti-acne pre¬parations for effectiveness versus Propionibacterium acnes in vivo. Cutis
1992; 49: 8-11.
42. Padilla Rs, McCabe JM, Becker LE. Topical tetracycline hydrochloride vs.
topical clindamycin phosphate in the treatment of acne. Int J Dermatol 1981;
20: 445-8.
43. Leyden JJ, McGinley KJ, Kligman AM. Tetracycline and minocycline tre¬atment: effects on skin surface lipid levels and Propionibacterium acnes. Arch
Dermatol 1982; 118: 19-22.
44. Mills OH, Marples RR, Kligman AM. Acne vulgaris. Oral therapy with tet-racycline and topical therapy with vitamin A. Arch Dermatol 1972; 106: 200¬3.
45. Smit F. Minocycline versus doxycycline in the treatment of acne vulgaris: a
double blind study. Dermatologica 1978; 157: 186-90.
46. Skidmore R, Kovach R, Walker C ve ark. Effects of subantimicrobial-do-se doxycycline in the treatment of moderate acne. J Fam Pract 2003; 52: 594¬7.
47. Gammon WR, Meyer C, Lantis S ve ark. Comperative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris:a do¬uble blind study. J Am Acad Dermatol 1986; 14: 183-6.
48. Eady EA, Cove JH, Holland KT, Cunlife WJ. Erythromycin resistant pro-pionibacteria in antibiotic treated acne patients: association with therapeutic
failure. Br J Dermatol 1989; 121: 51-7.
49. Hersle K. Trimethoprim-sulphamethoxazole in acne vulgaris: a double blind
study. Dermatologica 1972; 145: 187-91.
50. Poulos ET, Tedesco FJ. Acne vulgaris: double blind trial comparing tet-racycline and clindamycin. Arch Dermatol 1976; 112: 974-6.
51. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Der-
matol 2000; 39: 45-50.
52. Parsad D, Pandhi R, Nagpal R, Negi KS. Azithromycin monthly pulse vs daily doxycyline in the treatment of acne vulgaris. J Dermatol 2001; 28: 1-4.
53. Ferahbas A, Utas S, Aykol D, Borlu M, Uksal U. Clinical evaluation of ro-xithromycin: a double-blind, placebo-controlled and crossover trial in patients with acne vulgaris. J Dermatol 2004; 31: 6-9.
54. Rothman KF, Lucky AW. Acne vulgaris. Adv Dermatol 1993; 8: 347-74.
55. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treat¬ment. Dermatology 2003; 206(1): 37-53.
56. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 49: 200-10.
57. Shaw JC. Antiandrogen and hormonal treatment of acne. Dermatol Clin
1996; 14: 803-11.
58. Goodfellow A, Alaghband-Zadeh J, Carter G ve ark. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984;
111: 209-14.
59. Habif T. Clinical dermatology. St. Louis, Mosby Co, 1996; 162.
60. Cunliffe WJ, van de Kerkhof PC, Caputo R ve ark. Roaccutane treatment guidelines: results of international survey. Dermatology 1997; 194: 351-7.
61. Leyden J. The role of isotretinoin in the treatment of acne: personal obser¬vations. J Am Acad Dermatol 1998; 39: 45-8.
62. Shalita AR, Cunningham WJ, Leyden JJ ve ark. Isotretinoin treatment of acne and related disorders: an update. J Am Acad Dermatol 1983; 9: 629¬38.
Aile Hekimliği Dergisi
|
Turkish Journal of Family Practice | Cilt 9 | Sayı 2 | 2005 |
63. Wolverton SE. Retinoids. Systemic drugs for skin diseases'de. Ed.Wolver-ton SE, Wilkin JK. Philadelphia, Saunders, 1991; 187-218.
64. Layton AM, Knaggs H, Taylor J, Cunlife WJ. Isotretinoin for acne vulgaris-10 years later: a safe and successful treatment. Br J Dermatol 1993; 129: 292-6.
65. Lammer EF, Chen DT, Hour RM. Retinoic acid embryopathy. N Eng J
Med 1985; 313: 837-41.
66. Ferahbas A, Turan MT, Esel E, Utas S, Kutlugun C, Kilic CG. A pilot
study evaluating anxiety and depressive scores in acne patients treated with isotretinoin. J Dermatol Treat 2004; 15(3): 153-7.
67. Levine RM, Rasmussen JE. Intralesional corticosteroids in the treatment of nodulocystic acne. Arch Dermatol 1983; 119: 480-9.
68. Ruiz-Esparza J, Gomez JB. Nonablative radiofrequency for active acne vul-garis: the use of deep dermal heat in the treatment of moderate to severe ac¬tive acne vulgaris (thermotherapy): a report of 22 patients. Dermatol Surg
2003; 29: 333-9.
69. Elman M, Slatkine M, Harth Y. The effective treatment of acne vulgaris by a high-intensity, narrow band 405-420 nm light source. J Cosmet Laser Ther
2003; 5: 111-7.
70. Seaton ED, Charakida A, Mouser PE, Grace I, Clement RM, Chu AC.
Pulsed-dye laser treatment for inflammatory acne vulgaris: randomised cont¬rolled trial. Lancet 2003; 362: 1347-52.

Thank you for copying data from http://www.arastirmax.com